Clinical Trial Update: Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on the Triple-B study comparing carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumab as first-line therapy …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• CARBOPLATIN (Carboplatin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING